The Chemours Company $CC Holdings Increased by Inspire Investing LLC

Inspire Investing LLC grew its stake in shares of The Chemours Company (NYSE:CC) by 35.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,017 shares of the specialty chemicals company’s stock after buying an additional 8,861 shares during the quarter. Inspire Investing LLC’s holdings in Chemours were worth $389,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC grew its stake in shares of Chemours by 1,115.2% in the 1st quarter. GAMMA Investing LLC now owns 18,617 shares of the specialty chemicals company’s stock worth $252,000 after purchasing an additional 17,085 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of Chemours by 170.7% in the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company’s stock worth $30,000 after purchasing an additional 1,444 shares during the last quarter. Yousif Capital Management LLC grew its stake in shares of Chemours by 6.1% in the 1st quarter. Yousif Capital Management LLC now owns 61,418 shares of the specialty chemicals company’s stock worth $831,000 after purchasing an additional 3,510 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Chemours in the 1st quarter worth approximately $822,000. Finally, Janney Montgomery Scott LLC grew its stake in shares of Chemours by 22.4% in the 1st quarter. Janney Montgomery Scott LLC now owns 31,886 shares of the specialty chemicals company’s stock worth $431,000 after purchasing an additional 5,843 shares during the last quarter. 76.26% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Denise Dignam acquired 4,068 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average cost of $12.06 per share, with a total value of $49,060.08. Following the completion of the transaction, the chief executive officer owned 191,546 shares of the company’s stock, valued at approximately $2,310,044.76. This trade represents a 2.17% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.47% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Truist Financial lifted their price objective on shares of Chemours from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, September 16th. Royal Bank Of Canada set a $19.00 price objective on shares of Chemours and gave the stock an “outperform” rating in a research note on Tuesday. Zacks Research raised shares of Chemours from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 27th. UBS Group lifted their price objective on shares of Chemours from $17.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, October 6th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Chemours in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $18.63.

Chemours Stock Performance

Chemours stock opened at $14.44 on Thursday. The firm’s 50 day simple moving average is $15.25 and its 200-day simple moving average is $13.00. The company has a market cap of $2.16 billion, a P/E ratio of -5.16 and a beta of 1.65. The company has a debt-to-equity ratio of 17.16, a current ratio of 1.68 and a quick ratio of 0.83. The Chemours Company has a fifty-two week low of $9.13 and a fifty-two week high of $22.38.

Chemours (NYSE:CC) last released its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.12. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The business had revenue of $1.62 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same period last year, the firm posted $0.38 earnings per share. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts predict that The Chemours Company will post 2.03 EPS for the current year.

Chemours Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 15th were given a dividend of $0.0875 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $0.35 dividend on an annualized basis and a yield of 2.4%. Chemours’s payout ratio is presently -12.50%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.